A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination with Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment